Newsbot

Hims & Hers Health short interest rises to 23% ahead of Q3 results

Short interest in Hims & Hers Health rose to 23%, making it one of the most shorted mid-cap stocks. Stock price slumped 65% from its 2025 peak of $72.78 to approximately $26. Analysts expect Q3 revenue to reach $892 million, up 49% YoY from prior year. Company expanded access to Eli Lilly’s Zepbound ($299/month) and Foundayo ($149/month). Annual revenue guidance was hiked to between $3.1 billion and $3.3 billion.

Courage And Failure Are The New Brand Strategy

In the AI era, brands need courage to make bold bets rather than safe choices. A deliberate failure strategy lets teams innovate and learn effectively from missteps.